Search Results
10
Everything
Search Filters
Tag
Clinical Trial
Helicore Biopharma Announces First Participant Dosed in Phase 1 Clinical Trial of HCR-188, a First-in-Class GIP Antagonist for the Treatment of Obesity
March 25, 2025 09:00 ET
|
Helicore Biopharma
Helicore Biopharma Announces First Participant Dosed in Phase 1 Clinical Trial of HCR-188, a First-in-Class GIP Antagonist for the Treatment of Obesity
Allogenica Secures €2.5 Million Grant to Advance Universal CAR-T Therapy and Strengthen France’s Biotherapy Leadership
March 19, 2025 06:00 ET
|
Allogenica
Allogenica Secures €2.5 Million Grant to Advance Universal CAR-T Therapy and Strengthen France’s Biotherapy Leadership Allogenica received a €2.5 million grant from the French government's France...
BioAegis Therapeutics to Highlight Lead Product Gelsolin’s Critical Role in Immune Function at Upcoming Conferences
March 18, 2025 14:25 ET
|
BioAegis Therapeutics
Phase 2 clinical trial will be presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) conference in Brussels, Belgium on March 19, 2025. COO Valerie Ceva will...
Kane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acne Trial
March 13, 2025 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, March 13, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) ("Kane Biotech" or "Kane") announces today that it has received approval from the Internal Review...
Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial
March 12, 2025 08:00 ET
|
Portage Biotech Inc.
DOVER, Del., March 12, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative...
Kaerus Bioscience Successfully Completes Phase 1 Trial and Demonstrates Proof of Mechanism with its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome
March 11, 2025 08:33 ET
|
Kaerus Bioscience
Kaerus announces its novel BK channel modulator KER-0193 is safe and well tolerated in Phase 1, also demonstrating proof of mechanism with EEG biomarker.
Kaerus Bioscience Successfully Completes Phase 1 Trial and Demonstrates Proof of Mechanism with its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome
March 11, 2025 06:00 ET
|
Kaerus Bioscience
Kaerus announces its novel BK channel modulator KER-0193 is safe and well tolerated in Phase 1, also demonstrating proof of mechanism with EEG biomarker.
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025
March 10, 2025 15:00 ET
|
Immunocore Holdings plc
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 IMC-M113V was well tolerated, with no dose-limiting toxicities Signals...
Eradivir announces Phase 2 human challenge study of EV25 in healthy adults infected with influenza
March 10, 2025 08:01 ET
|
Purdue Research Foundation
WEST LAFAYETTE, Ind., March 10, 2025 (GLOBE NEWSWIRE) -- Eradivir, a clinical-stage small molecule immunotherapy biotech company, announced it has begun a Phase 2 challenge study with its antiviral...
Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement
March 10, 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement